MALVERN, PA, Jul 09, 2010 (MARKETWIRE via COMTEX) --
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that
Mr. Armando Anido, Chief Executive Officer and President, will
provide a XIAFLEX launch and development update on Monday, July 12,
2010 at 8:30 a.m. ET. Dr. Clayton Peimer, Clinical Professor of
Orthopedics at Michigan State University and attending hand surgeon
at Marquette General Health System, will also present during the
call. The presentation slides to be used during the call will be
available on the "For Investors" section of the Auxilium web site
under the "Presentations" tab beginning at 7 a.m. ET on Monday, July
12, 2010. A web cast of the conference call and the presentation
slides will be available on the "For Investors" section of the
Auxilium web site under the "Events" tab beginning at 8:30 a.m. ET on
Monday, July 12, 2010. A question and answer session will follow the
presentations.
Conference call details:
Date: Monday, July 12, 2010
Time: 8:30 a.m. ET
Dial-in (U.S.): 866-362-4831
Dial-in (International): 617-597-5347
Web cast and slides: http://ir.auxilium.com/
Passcode: AUXILIUM
To access an audio replay of the call:
Access number (U.S.): 888-286-8010
Access number (International): 617-801-6888
Replay Passcode #: 14203618
To listen to the audio web cast of the presentation and view the
slides during or after the event, please visit:
http://ir.auxilium.com. The replay will be available for ninety days
after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical
company with a focus on developing and marketing products to
predominantly specialist audiences, such as urologists,
endocrinologists, certain targeted primary care physicians, hand
surgeons, subsets of orthopedic, general, and plastic surgeons who
focus on the hand, and rheumatologists. Auxilium markets XIAFLEX(R)
(collagenase clostridium histolyticum) for the treatment of adult
Dupuytren's contracture patients with a palpable cord and Testim(R)
1%, a topical testosterone gel, for the treatment of hypogonadism.
Auxilium has four projects in clinical development. XIAFLEX is in
phase IIb of development for the treatment of Peyronie's disease and
is in phase II of development for treatment of Frozen Shoulder
syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product
candidate for the treatment of overactive bladder (AA4010) and its
fentanyl pain product using its transmucosal delivery system are in
phase I of development. The Company is currently seeking a partner to
further develop these product candidates. Auxilium has rights to
additional pain products and products for hormone replacement and
urologic disease using its transmucosal film delivery system.
Auxilium also has options to all indications using XIAFLEX for
non-topical formulations. For additional information, visit
http://www.auxilium.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
This release contains "forward-looking-statements" within the meaning
of The Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's intention to provide a launch and
development update on XIAFLEX; and products in development for
Peyronie's disease, Frozen Shoulder syndrome, overactive bladder,
pain, hormone replacement and urologic disease; and all other
statements containing projections, statements of future performance
or expectations, our beliefs or statements of plans or objectives for
future operations (including statements of assumption underlying or
relating to any of the foregoing). Forward-looking statements can
generally be identified by words such as "believe," "appears," "may,"
"could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and other words and terms of similar
meaning in connection with any discussion of projections, future
performance or expectations, beliefs, plans or objectives for future
operations (including statements of assumption underlying or relating
to any of the foregoing). Actual results may differ materially from
those reflected in these forward-looking statements due to various
factors, including further evaluation of clinical data, results of
clinical trials, decisions by regulatory authorities as to whether
and when to approve drug applications, and general financial,
economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries and those discussed in
Auxilium's Annual Report on Form 10-K for the year ended December 31,
2009 and in Auxilium's Quarterly Report on Form 10-Q for the period
ended March 31, 2010 under the heading "Risk Factors," which are on
file with the Securities and Exchange Commission (the "SEC") and may
be accessed electronically by means of the SEC's home page on the
Internet at http://www.sec.gov or by means of Auxilium's home page on
the Internet at http://www.Auxilium.com under the heading "For
Investors -- SEC Filings." There may be additional risks that
Auxilium does not presently know or that Auxilium currently believes
are immaterial which could also cause actual results to differ from
those contained in the forward-looking statements. Given these risks
and uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements.
In addition, forward-looking statements provide Auxilium's
expectations, plans or forecasts of future events and views as of the
date of this release. Auxilium anticipates that subsequent events and
developments will cause Auxilium's assessments to change. However,
while Auxilium may elect to update these forward-looking statements
at some point in the future, Auxilium specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Auxilium's assessments as of any date
subsequent to the date of this release.
For More Information, Contact:
James E. Fickenscher
CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact
William Q. Sargent, Jr.
V.P., IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact
SOURCE: Auxilium Pharmaceuticals, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=583CFF5C5C99E843
http://www2.marketwire.com/mw/emailprcntct?id=C6C95FCB665461FD
